Maraviroc
Author:
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmacology,General Medicine
Link
http://www.nature.com/articles/nrd2490.pdf
Reference10 articles.
1. Flexner, C. HIV drug development: the next 25 years. Nature Rev. Drug Disc. 6, 959–966 (2007).
2. Tsibris, A. M. & Kuritzkes, D. R. Chemokine antagonists as therapeutics: focus on HIV-1. Annu. Rev. Med. 58, 445–459 (2007).
3. Dorr, P. et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49, 4721–4732 (2005).
4. Food and Drug Administration. FDA labelling information [online] , (2007).
5. Fätkenheuer, G. et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nature Med. 11, 1170–1172 (2005).
Cited by 50 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. New perspective of small-molecule antiviral drugs development for RNA viruses;Virology;2024-06
2. Structure-guided design and cloning of peptide inhibitors targeting CDK9/cyclin T1 protein-protein interaction;Frontiers in Pharmacology;2024-05-14
3. Synthetic and Clinical Perspectives of Evotaz: An Overview;Mini-Reviews in Medicinal Chemistry;2024-03
4. The chemokine receptor CCR5: multi-faceted hook for HIV-1;Retrovirology;2024-01-23
5. A Combination of Novel HIV-1 Protease Inhibitor and Cytochrome P450 (CYP) Enzyme Inhibitor to Explore the Future Prospective of Antiviral Agents: Evotaz;Current HIV Research;2023-09-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3